中波高能紫外线联合0.03%他克莫司软膏治疗儿童白癜风的效果及安全性分析

摘要
图/表
参考文献(15)
相关文章 (13)

全文: PDF (0 KB) HTML (28 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察对儿童白癜风采用中波高能紫外线联合0.03%他克莫司软膏治疗的安全性及对治疗影响因素的分析。方法将2014年3月～2017年3月在我院就诊的120例儿童白癜风患者作为研究对象，收集其临床资料进行回顾性分析；按照治疗方案不同，将患儿分成观察组和对照1组、对照2组，每组各40例。观察组患儿采用中波高能紫外线联合0.03%他克莫司软膏治疗，1～2次/周，12周为1疗程；对照1组患儿采用单纯紫外线治疗，对照2组仅给予他克莫司软膏外涂，分析三组患儿治疗效果、影响因素及安全性。结果观察组患儿治疗总有效率为67.50%（27/40），显著高于对照1组的50.00%（20/40）和对照2组的42.5%（17/40），差异有统计学意义（P＜0.05），对照1组及对照2组间差异无统计学意义（P＞0.05）；观察组患儿皮损复色起始时间（1.52±0.66）个月，显著低于对照 1组的（1.90±0.95）个月和对照 2组的（1.95±0.90）个月，差异有统计学意义（P＜0.05），两对照组组间差异无统计学意义（P＞0.05）；观察组患儿头面部、躯干部、四肢及肢端有效率均高于对照1组、对照2组，差异有统计学意义（P＜0.05）；而对照组1组则高于对照2组，组间比较差异无统计学意义（P＞0.05）；观察组患儿初次治疗不良反应发生率为45.00%，与对照1组的45.00%一致，但高于对照2组的40.00%，对照1组、对照2组差异无统计学意义（P＞0.05）。结论对儿童白癜风采用中波高能紫外线联合0.03%他克莫司软膏治疗，其治疗效果主要受部位、病程、治疗频率影响，副作用较小，安全性较高，效果理想，值得临床推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	梁兴龙
	严军
	冯帆

关键词 ：中波高能紫外线, 他克莫司软膏, 儿童白癜风, 治疗效果, 安全性, 影响因素分析

Abstract：ObjectiveTo observe the safety of medium-wave high-energy ultraviolet irradiation combined with 0.03%Tacrolimus Ointment in the treatment of vitiligo in children and the analysis of its influencing factors.MethodsA total of 120 patients diagnosed as pediatric vitiligo treated in our hospital from March 2014 to March 2017 were selected as research objects.Their clinical data were collected and analyzed retrospectively.According to the different therapeutic regimen,they were divided into the observation group,control group 1,and control group 2 evenly.In the observation group,40 cases were treated with medium-wave high-energy ultraviolet irradiation combined with 0.03%Tacrolimus Ointment,1 to 2 times per week,12 weeks for one course of treatment.In the control group 1,only ultraviolet radiation was used,and in the control group 2,only external application of Tacrolimus Ointment was adopted.The therapeutic effect,influencing factors,and safety among the three groups were analyzed.ResultsIn the observation group,the total effectiveness rate was 67.50%(27/40),significantly higher than that of control group 1 accounting for 50.00%(20/40),and control group 2 accounting for 42.5%(17/40),the difference was statistically significant(P＜0.05).There was no significant difference between the control group 1 and control group 2 (P＞0.05).The onset time of color restoration of skin lesions in the observation group was (1.52±0.66)months,greatly lower than that in the control group 1 and control group 2,(1.90±0.95)months and(1.95±0.90)months(P＜0.05),but there was no significant difference between the last two groups(P＞0.05).The effectiveness rates of the head and face,the trunk,four limbs,and the end of extremities were all higher than those in the control group 1 and control group 2,but no statistical difference was detected when comparing the data between the control groups(P＞0.05).The incidence of adverse reaction for the first time in the observation group was 45.00%,which was the same as that in the control group 1,but slightly higher than that in control group 2 accounting for 40.00%.There was no significant difference between control groups (P＞0.05).Conclusion In the treatment of children with vitiligo,application of medium-wave high-energy ultraviolet irradiation combined with 0.03%Tacrolimus Ointment can obtain a favorable effect in mild side effect and high safety and the therapeutic effects are mainly influenced by the affected site,course of disease，and treatment frequency,and is worthy of clinical promotion.

Key words： Medium-wave high-energy ultraviolet irradiation Tacrolimus Ointment Pediatric vitiligo Therapeutic effect Safety Influencing factors analysis

作者简介: 梁兴龙（1984-），男，广东省茂人，硕士，主治医师，研究方向：白癜风、医学美容

引用本文:

梁兴龙 ;严军; 冯帆. 中波高能紫外线联合0.03%他克莫司软膏治疗儿童白癜风的效果及安全性分析[J]. 中国当代医药, 2018, 25(3): 36-38.
LIANG Xing-long ;YAN Jun; FENG Fan. Efficacy and safety analysis of medium-wave high-energy ultraviolet irradiation combined with 0.03%Tacrolimus Ointment in the treatment of children with vitiligo. 中国当代医药, 2018, 25(3): 36-38.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I3/36

[1]	蒋跃根，曾学思，程险峰，等.抗核抗体、免疫球蛋白及补体在儿童白癜风疾病中的价值探讨[J].检验医学与临床，2016，13（6）：743-745.
[2]	车丽颖.他克莫司软膏与窄谱中波紫外线联合治疗白癜风疗效观察[J].中国医药科学，2011，1（11）:44.
[3]	王希晶，梅淑清，王娜，等.高能紫外线联合0.1%他克莫司软膏外搽治疗59例白癜风临床观察[J].现代诊断与治疗，2015，26（12）:2711-2712.
[4］	王露，陈华全.白癜风免疫学机制研究进展[J].皮肤性病诊疗学杂志，2013，20（2）：133-135.
[5]	李舒丽，刘玲，坚哲，等.儿童白癜风1125例的临床特征与治疗总结[J].中国美容医学，2012，21（9）：1586-1589.
[6]	俞晨，李强，李春英，等.窄谱中波紫外线联合中药治疗白癜风的临床疗效对比分析[J].中国美容医学，2012，21（9）：1559-1561.
[7]	杨慧兰，林挺，毕建军，等.他克莫司软膏联合308 nm准分子激光治疗儿童局限性白癜风[J].中国美容医学，2012，21（9）：1564-1566.
[8］	吕萍.窄谱中波紫外线联合他克莫司软膏治疗白癫风疗效观察[J].当代医学，2010，16（27）:152.
[9］	欧柏生，魏飞，冯杲，等.中医药治疗白癜风国内动物实验研究概述[J].实用医药杂志，2013，30（4）：361-363.
[10]	吴成.白癜风细胞免疫研究新进展[J].医学综述，2012，18（9）：1338-1340.
[11]	刘群英.细胞免疫与白癜风[J].华夏医学，2014，27（3）：194-197.
[12]	刘力萌，万屏.白癜风免疫学研究进展[J].皮肤病与性病，2012，34（3）：140-141.
[13]	孟艳鲜.他克莫司软膏联合窄谱中波紫外线治疗白癜风疗效和安全性探讨[J].中国实用医药，2015，10（29）：152-153.
[14]	刘树雷，廖军，邓晓玲，等.窄谱中波紫外线联合他克莫司软膏治疗白癜风的临床疗效观察[J].激光杂志，2014，35（3）：58-59.
[15]	俞劲松，居婷.高能紫外线联合0.03%他克莫司软膏治疗儿童白癜风的疗效和安全性[J].医疗装备，2016，29（24）：102-103.